On November 17, 2022, the Ministry of Health and Prevention published the Order in the Official Journal of the French Republic on the extension of the national newborn screening by laboratory diagnostics to seven more diseases (inborn errors of metabolism): leucinosis, homocystinuria, tyrosinemia type 1, glutaric aciduria type 1, isovaleric aciduria, long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, and primary carnitine deficiency.
These inborn errors of metabolism will be screened by tandem mass spectrometry according to the requirements and conditions described in the Order. Screening for these diseases will be carried out from January 1, 2023.
See the details in French here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).